In this study, the proportion of patients with HER2-positive HAS was 28.0%, which is significantly higher than the HER2 positivity rate observed in the ToGA study of patients with conventional gastric adenocarcinoma.4 Here, ERBB2 is linked to gastric adenocarcinoma.